DE69326227D1 - Verfahren zur Isolation von hoch angereicherten Faktoren IX, X und II vom Prothrombin komplex oder menschlichem Plasma - Google Patents

Verfahren zur Isolation von hoch angereicherten Faktoren IX, X und II vom Prothrombin komplex oder menschlichem Plasma

Info

Publication number
DE69326227D1
DE69326227D1 DE69326227T DE69326227T DE69326227D1 DE 69326227 D1 DE69326227 D1 DE 69326227D1 DE 69326227 T DE69326227 T DE 69326227T DE 69326227 T DE69326227 T DE 69326227T DE 69326227 D1 DE69326227 D1 DE 69326227D1
Authority
DE
Germany
Prior art keywords
human plasma
isolation
prothrombin complex
highly enriched
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69326227T
Other languages
English (en)
Other versions
DE69326227T2 (de
Inventor
Silvana Arrighi
Francesco Norelli
Maria Giuseppina Borri
Enzo Bucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISI IST SIEROVACCINOGENO ITAL
Sclavo SpA
Original Assignee
ISI IST SIEROVACCINOGENO ITAL
Sclavo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISI IST SIEROVACCINOGENO ITAL, Sclavo SpA filed Critical ISI IST SIEROVACCINOGENO ITAL
Application granted granted Critical
Publication of DE69326227D1 publication Critical patent/DE69326227D1/de
Publication of DE69326227T2 publication Critical patent/DE69326227T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69326227T 1992-03-27 1993-03-22 Verfahren zur Isolation von hoch angereicherten Faktoren IX, X und II vom Prothrombin komplex oder menschlichem Plasma Expired - Lifetime DE69326227T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITFI920078A IT1262899B (it) 1992-03-27 1992-03-27 Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano

Publications (2)

Publication Number Publication Date
DE69326227D1 true DE69326227D1 (de) 1999-10-07
DE69326227T2 DE69326227T2 (de) 2000-02-17

Family

ID=11350034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326227T Expired - Lifetime DE69326227T2 (de) 1992-03-27 1993-03-22 Verfahren zur Isolation von hoch angereicherten Faktoren IX, X und II vom Prothrombin komplex oder menschlichem Plasma

Country Status (6)

Country Link
US (1) US5378365A (de)
EP (1) EP0617049B1 (de)
AT (1) ATE184018T1 (de)
DE (1) DE69326227T2 (de)
ES (1) ES2138603T3 (de)
IT (1) IT1262899B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
DE19625642A1 (de) * 1996-06-26 1998-01-08 Max Planck Gesellschaft Verfahren zur Herstellung einer Antidotausgangssubstanz für natürliche und synthetische Thrombininhibitoren
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
SE0203551D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
GB0614315D0 (en) 2006-07-19 2006-08-30 Ge Healthcare Bio Sciences Ab Chromatography columns, systems and methods
GB0704603D0 (en) * 2007-03-09 2007-04-18 Ge Healthcare Bio Sciences Ab Packing system and method for chromatography columns
US9597610B2 (en) * 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
US9597611B2 (en) 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US7934704B2 (en) * 2007-10-16 2011-05-03 Environmental Dynamics, Inc. Retrievable diffuser module with internal ballast/buoyancy chamber
EP2373677B1 (de) * 2008-12-02 2016-03-23 Novo Nordisk Health Care AG Polypeptidreinigung
JP6250931B2 (ja) 2010-01-18 2017-12-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 血液凝固因子の精製
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
WO2012135415A1 (en) 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (de) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5286849A (en) * 1992-07-14 1994-02-15 Alpha Therapeutic Corporation Purification of factor IX

Also Published As

Publication number Publication date
ATE184018T1 (de) 1999-09-15
DE69326227T2 (de) 2000-02-17
ITFI920078A1 (it) 1993-09-27
EP0617049B1 (de) 1999-09-01
ITFI920078A0 (it) 1992-03-27
US5378365A (en) 1995-01-03
ES2138603T3 (es) 2000-01-16
EP0617049A1 (de) 1994-09-28
IT1262899B (it) 1996-07-22

Similar Documents

Publication Publication Date Title
DE69326227D1 (de) Verfahren zur Isolation von hoch angereicherten Faktoren IX, X und II vom Prothrombin komplex oder menschlichem Plasma
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
EP0391526A3 (de) Reinigungsverfahren für Antikörper
DE69435170D1 (de) Extrakorporeale Vorrichtungen zur Adsorption durch Affinität
MX9707909A (es) Purificacion de anticuerpos.
DE69124172D1 (de) Verfahren zur Reinigung von Edelgas
ATE249244T1 (de) Aktivierte verbindungen und verfahren zur herstellung und reiningung
DE69316954D1 (de) Reinigung von Sauerstoff durch Adsorption
HK1055307A1 (en) Antibody purification by ion exchange chromatography
GR3032728T3 (en) Purification of alpha-1 proteinase inhibitor using novel chromatographic separation conditions
DE59004059D1 (de) Verfahren zur Entfernung von Jod und Jodverbindungen aus wasserstoffhaltigen Gasen und Dämpfen.
FR2665449B1 (fr) Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
ATE47883T1 (de) Verfahren zur selektiven erhoehung des anteiles von einzelnen hauptkomponenten des teicoplanin a2-komplexes.
DK0578347T3 (da) Separation af metalioner på en anionbytterharpiks ved kromatografisk eluering
ATE98649T1 (de) Reinigung von lfa-3.
DE3887095D1 (de) Verfahren zur Isolierung und Reinigung von Hirudin.
AU574133B2 (en) Concentration and purification of hydrogen gas by adsorption process
DE69025961D1 (de) Verfahren zur Reinigung von Interleukin-4
DE3881895D1 (de) Verfahren zur reinigung von vitamin-k-abhaengigen blutgerinnungsfaktoren.
DE3678633D1 (de) Verfahren zur reinigung vom humanen tumornekrosefaktor.
EP0720618A4 (de) Verfahren zur reinigung von "basic" fibroblasten wachstumsfaktor
DE68908801D1 (de) Verfahren zur Reinigung von Dihydroxyphenolen.
GB2267703B (en) Sorbent for treatment of effluent gas stream
GB2234451B (en) Process for the fine purification of gases
FR2644064B1 (fr) Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: SEITZ, R., DIPL.-ING.UNIV., PAT.-ANW., 80538 MUENC